AquaBounty Technologies expects its biotech salmon, which grows twice as fast as traditional salmon, to be approved by the FDA before the year ends. "There have been no new legal issues, no new regulatory issues, no new environmental issues raised," CEO Ronald Stotish said at the BIO International Convention. The public comment period ends on Friday, and the FDA's decision could come 150 to 180 days later, Stotish said.

Related Summaries